Abstract 338P
Background
Nasal type NKTCL refers to upper aerodigestive tract (UAT) involvement while non-nasal type does not involve UAT at initial diagnosis. Since NKTCLs are predominantly nasal type, there remains little knowledge of non-nasal type disease.
Methods
Newly diagnosed advanced-stage non-nasal and nasal type NKTCL patients from two large cancer centers in the past 10-15 years were retrospectively collected.
Results
The study included 56 non-nasal type NKTCL patients with 139 nasal cases as controls. The non-nasal type NKTCLs exhibited higher Ki-67 expression levels compared to nasal cases (P=0.011) with no significant differences in other baseline features. With a median follow-up of 75.03 months, the non-nasal group showed slightly inferior overall survival (OS) compared to the nasal group (median OS [mOS]: 14.57 vs. 21.53 months, P=0.120). ECOG score≥2 (hazard ratio [HR]=2.18, P=0.039) and LDH elevation (HR=2.44, P=0.012) were correlated with worse OS, and the modified nomogram-revised risk index (NRI) and international prognostic index (IPI) functioned effectively for prognostic stratification. Multi- compared to single-modality therapy led to significantly superior progression-free survival (PFS) and OS (median PFS [mPFS]: 11.53 vs. 2.03 months, P=0.001; mOS: 52.80 vs. 7.70 months, P=0.006). Chemoradiotherapy combination significantly improved survival compared to other modalities (mPFS: 14.00 vs. 3.47 months, P=0.050; mOS: 56.40 vs. 9.30 months, P=0.046), and gemcitabine- compared to non-gemcitabine-based regimens showed a trend towards slightly improved outcomes (mPFS: 10.43 vs. 3.40 months, P=0.106; mOS: 25.13 vs. 9.30 months, P=0.125). Table: 338P
Prognostic stratification of advanced-stage non-nasal type ENKTLs
Model | Variable | Risk stratification | Score | Non-nasal type (n=56) (%) | Nasal type (n=139) (%) |
Modified NRI | Age (>60 vs. ≤60 years)ECOG score (≥2 vs. 0-1) Elevated LDH (yes vs. no) | low risk | 0 | 16(28.6) | 46(33.1) |
high risk | 1 | 30(53.6) | 71(51.1) | ||
2 | 5(8.9) | 20(14.4) | |||
3 | 5(8.9) | 2(1.4) | |||
Modified PINK | Age (>60 vs. ≤60 years) Non-nasal type (yes vs. no) | / | 0 | 0 | 121(87.1) |
1 | 45(80.4) | 18(12.9) | |||
2 | 11(19.6) | 0 | |||
Modified IPI | Age (>60 vs. ≤60 years)ECOG score (≥2 vs. 0-1)Elevated LDH (yes vs. no)Extranodal involvement (≥2 vs. 0-1) | low risk | 0 | 2(3.6) | 6(4.3) |
1 | 16(28.6) | 46(33.1) | |||
high risk | 2 | 28(50.0) | 66(47.5) | ||
3 | 5(8.9) | 19(13.7) | |||
4 | 5(8.9) | 2(1.4) |
Conclusions
Advanced-stage non-nasal type NKTCL patients could achieve comparable prognosis with nasal cases after rational comprehensive therapy. Potent therapy is preferred in young patients with previously untreated disease, good performance status, and relatively low tumor burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chinese Geriatric Oncology Society Scientific Research Fund (CGOS-06-2014-1-1-01600).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract